Clinical drug
lazertinib 240 MG Oral Tablet
240 MG · Oral Tablet · oral
A form of lazertinib →
lazertinib 240 MG Oral Tablet — Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Strength, form, class, interactions & more.
Active ingredient
Classification
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsKinase Inhibitor
Drug interactions
Lazertinib has several interactions with CYP3A4 and BCRP substrates and inducers.
- majorstrong and moderate CYP3A4 inducers — decreased lazertinib concentrations, which may reduce efficacy
- moderateCYP3A4 substrates — increased concentrations of CYP3A4 substrates, which may increase the risk of adverse reactions
- moderateBCRP substrates — increased concentrations of BCRP substrates, which may increase the risk of adverse reactions
Real-world adverse events (FAERS)
Rash114Infusion Related Reaction68Neuropathy Peripheral36Fatigue35Off Label Use33Paronychia33Diarrhoea29Dyspnoea24
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication